DATROWAY demonstrated statistically significant and clinically meaningful improvement in overall survival as 1st-line therapy for patients with metastatic triple-negative breast cancer for whom ...

(Alliance News) - Daiichi Sankyo Co Ltd on Thursday said the EU has validated an application for Datroway as a first-line treatment for patients with metastatic triple negative breast cancer who are ...

A sign is pictured during the unveiling of AstraZeneca's new manufacturing facility, to be operational in the coming months with an initial focus on T-cell therapies, in Rockville, Maryland, U.S., May ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall ...

(Reuters) -AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the ...

On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...